about
Toward precision medicine in neurological diseasesCancer Cell Fusion: Mechanisms Slowly UnravelClinicians' expectations for gene-driven cancer therapyEpithelial cancers in the post-genomic era: should we reconsider our lifestyle?Prospective molecular profiling of canine cancers provides a clinically relevant comparative model for evaluating personalized medicine (PMed) trialsIntratumoral heterogeneity: Role of differentiation in a potentially lethal phenotype of testicular cancerOne hundred years of somatic mutation theory of carcinogenesis: is it time to switch?Validation and utilisation of high-coverage next-generation sequencing to deliver the pharmacological audit trailMinimal residual disease in acute myeloid leukaemiaThe oncogenic STP axis promotes triple-negative breast cancer via degradation of the REST tumor suppressorHomologous Mutation to Human BRAF V600E Is Common in Naturally Occurring Canine Bladder Cancer--Evidence for a Relevant Model System and Urine-Based Diagnostic Test.An improved understanding of cancer genomics through massively parallel sequencing.A roadmap for precision medicine in the epilepsies.Semiautomated isolation and molecular characterisation of single or highly purified tumour cells from CellSearch enriched blood samples using dielectrophoretic cell sorting.NRAS germline variant G138R and multiple rare somatic mutations on APC in colorectal cancer patients in Taiwan by next generation sequencing.Identification of mutations in the PYRIN-containing NLR genes (NLRP) in Head and Neck Squamous Cell Carcinoma.Intratumoral heterogeneity and chemoresistance in nonseminomatous germ cell tumor of the testis.Cancer Stem Cells: Plasticity Works against Therapy.Personalized therapy for breast cancer: a dream or a reality?Acquired somatic TP53 or PIK3CA mutations are potential predictors of when polyps evolve into colorectal cancer.Health economics and outcomes research: informing companion diagnostic development, guidelines, adoption and reimbursement.
P2860
Q26748951-90DA99AA-13DA-4CFF-AE77-F499FEE79ACEQ28076643-A2E2945E-FD79-4751-B5FD-BBAD6AEB5D73Q28083844-7C3DB03B-D691-4BD7-A4E3-88447516D0DAQ28391921-C29C7F21-BC8F-4FFC-9E0F-FC5B20C326D8Q28540955-22ACF547-7036-4042-B875-0409F114BF82Q30489149-10BFEC47-1FFC-4450-962D-9C04FFC8623BQ33601588-C0E15FA4-27D3-4A9D-9E2F-308E914EF79EQ34113504-A28CA1DF-2076-47CB-B7C5-D0D5B91F24DAQ34179265-1262686C-BEE4-4C55-8BB7-3E233D128CCAQ35592084-12AC5F64-CBD8-427A-92ED-D54876770CF8Q35752069-66A93394-7E07-4383-A219-29F3573A94F6Q35801066-7BC24C3D-D07B-4A06-9587-C5B4AAAD5C87Q36330968-0EE0B9AB-5FD9-4481-9162-BECC7B6C1C0AQ36747333-31BB52D1-0CD4-4A37-B367-FA341A2F0C83Q37437222-8D004B6F-D8A0-45FC-80D7-C08D13C6E03FQ37499597-267BC131-41B2-4219-97C4-D8EA7DD35756Q37699230-A5CFD433-2CCD-4DAC-912B-55033469201BQ38707592-CE578C55-97B2-4495-AAAA-CD81452F5993Q39374969-DB3D66B8-C5BB-498E-9BD3-D9DFA5345862Q42700799-D61A5DDC-B75E-46C9-BCD4-6260725F976EQ43863632-996177FC-31BB-4A87-9B91-7B6AC36ED20D
P2860
description
2012 nî lūn-bûn
@nan
2012 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
What are we learning from the cancer genome?
@ast
What are we learning from the cancer genome?
@en
What are we learning from the cancer genome?
@nl
type
label
What are we learning from the cancer genome?
@ast
What are we learning from the cancer genome?
@en
What are we learning from the cancer genome?
@nl
prefLabel
What are we learning from the cancer genome?
@ast
What are we learning from the cancer genome?
@en
What are we learning from the cancer genome?
@nl
P2093
P2860
P1476
What are we learning from the cancer genome?
@en
P2093
Eric A Collisson
Joe W Gray
Raymond J Cho
P2860
P2888
P304
P356
10.1038/NRCLINONC.2012.159
P407
P577
2012-09-11T00:00:00Z
P6179
1016561608